Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-11-12 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
监事会关于2022年股权激励计划预留授予事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion regarding the 2022 equity incentive plan reserved grant matters. It discusses compliance with company law, securities law, listing rules, and internal company articles, and confirms the legitimacy and qualifications of the incentive recipients. It is a formal announcement related to equity incentive plan verification rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document is relatively short (986 characters) and is a formal announcement of a supervisory board opinion on a specific corporate governance matter related to equity incentives. This fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-11-12 Chinese
2022年股权激励计划预留权益授予公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the 2022 equity incentive plan reserved rights grant by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes information about board and supervisory meetings, approval processes, grant details, performance targets, legal and financial advisor opinions, and the impact on financials. The document is not a full financial report but an announcement of a specific corporate action related to stock options and equity incentives. It does not contain financial statements or quarterly/yearly financial results. It is not a report publication announcement since it contains substantive details about the equity incentive plan and its approval. The document fits best under the category of Capital/Financing Update (CAP) because it relates to the issuance of stock options and equity incentives, which affect the company's capital structure and financing activities.
2023-11-12 Chinese
2022年股权激励计划预留授予激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the 2022 equity incentive plan, specifically the reserved grant list of incentive recipients. It includes details about stock options allocated to core employees and their proportion relative to total stock options and share capital. The document is short (864 characters) and primarily serves as an announcement of the equity incentive plan details rather than a full report or detailed financial statement. It does not contain comprehensive financial data or management discussion but rather a specific update on share-based compensation allocation. This fits best under the category of Capital/Financing Update (CAP), as it relates to equity incentive plans and stock option grants, which are capital structure related activities.
2023-11-12 Chinese
第三届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 15th meeting of the third Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results related to a stock option incentive plan. There is no financial data, no detailed report, and no reference to an annual or interim report. The document is an official announcement of a board/management decision regarding stock options, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-11-12 Chinese
关于北京三元基因药业股份有限公司2022年股权激励计划预留权益授予相关事项的法律意见书
Regulatory Filings
2023-11-12 Chinese
第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 13th meeting of the 3rd Board of Directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results, specifically regarding a stock option grant plan. There is no financial data, audit information, or report publication mentioned. The content focuses on board decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2023-11-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.